Sarepta Therapeutics (NASDAQ:SRPT) Issues Quarterly Earnings Results, Beats Estimates By $0.42 EPS

Sarepta Therapeutics (NASDAQ:SRPT) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42, FiscalAI reports. The firm had revenue of $401.25 million during the quarter, compared to the consensus estimate of $366.39 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The firm’s revenue was down 34.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.02 earnings per share.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

• 2026 net product revenue guidance was narrowed to $1.2 billion–$1.3 billion, with second-half revenue expected to be modestly below the first half and ELEVIDYS revenue likely lower in the third quarter. Management said improving enrollment forms may contribute more meaningfully to revenue in 2027.
• Sarepta reported Q2 GAAP operating income of $13 million and non-GAAP operating income of $86 million, while cash and investments increased by approximately $197 million to $945 million. The company also raised collaboration and other revenue guidance to $550 million–$600 million, primarily due to higher Roche contract-manufacturing revenue.
• ELEVIDYS enrollment-form activity improved sequentially as the expanded commercial organization became fully operational, with increased engagement from returning sites and interest from new referral sites. However, management cautioned that the typical approximately six-month enrollment-to-infusion timeline delays the revenue impact.
• The FDA accepted supplemental applications for AMONDYS 45 and VYONDYS 53 seeking conversion from accelerated to traditional approval, with a target action date of February 28, 2027. Sarepta said the applications are supported by the ESSENCE confirmatory study and substantial real-world evidence.
• Key pipeline catalysts include second-half 2026 interim MAD-study data for the SRP-1001 FSHD and SRP-1003 DM1 programs, early Huntington’s disease proof-of-biology data expected in early 2027, and full 12-week data from ELEVIDYS ENDEAVOR cohort 8 expected in the first quarter of 2027.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded down $0.46 on Wednesday, reaching $15.93. 3,080,925 shares of the company traded hands, compared to its average volume of 3,160,738. The stock has a market capitalization of $1.68 billion, a PE ratio of -16.59, a P/E/G ratio of 0.18 and a beta of 0.23. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. The company’s 50 day moving average is $16.95 and its 200-day moving average is $18.55. Sarepta Therapeutics has a fifty-two week low of $14.68 and a fifty-two week high of $25.32.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Royal Bank Of Canada increased their price objective on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research note on Tuesday, April 7th. Piper Sandler reduced their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. Wall Street Zen raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 4th. HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Finally, Weiss Ratings raised shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and six have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $24.72.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. iSAM Funds UK Ltd purchased a new stake in Sarepta Therapeutics during the third quarter valued at about $25,000. Kestra Advisory Services LLC purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $25,000. Ancora Advisors LLC boosted its stake in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the period. Allworth Financial LP grew its position in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,256 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.